Andrés Briseño

Médico Patologo Pulmonar #aficionadodelaradiologiadetorax #HorseLover

[Dr. Arkadip MD @pathognosis22]

#Grossing #Prostate #TNM #Pathology #pathognosis

[Diego A. Díaz-García @diegoadiazg]

🫁 Unresectable Stage III NSCLC: Current State of the Art.

The management of unresectable stage III NSCLC continues to evolve. cCRT remains the backbone of treatment, while consolidation durvalumab (PACIFIC) and osimertinib for EGFR-mutated disease (LAURA) have redefined the standard of care.

Precision radiotherapy and biomarker-driven strategies are shaping the next era of treatment.

📖 Am Soc Clin Oncol Educ Book
DOI 👉🏻 https://t.co/NCOmck4ZXI

#CánCare #NSCLC #lcsm #thoraciconcology #immunotherapy #precisiononcology

[Luis Moreno Sánchez @radioncoluis]

Updates in Small Cell Lung Cancer Treatment: No Longer Too Small to Ignore—A Review of Recent Therapeutic Advances.

https://t.co/aSWFoomDiI

[Dr Rupam Manna MD @DrRupamOncology]

NSGCT (Non-Seminomatous Germ Cell Tumor) – Staging with Management
High-yield one-pager covering:
✅ TNM Stage Grouping (IA–IIIC) with management options
✅ IGCCCG Risk Classification – Good / Intermediate / Poor (criteria + BEP cycles + cure rates)
✅ Post-chemo residual mass approach (PC-RPLND indications & pathology)
✅ Exam-oriented flow + Key Viva Pearls
Perfect for DrNB/MD Oncology exams, viva & daily practice.
Verified as per latest NCCN v1.2026, ESMO & IGCCCG standards ✅
Save this for your prep!
@DrRupamOncology
#NSGCT #TesticularCancer #GermCellTumor #Oncology #MedicalOncology #DrNB #MedEd #TestisCancer

[Felipe Templo Jr. ,MD, MBA 🕊 @thejourneymate]

Immunohistochemistry 101 🔬

(c): Sumit Kumar

[Human Pathology @Human_Pathology]

New in #HumPathol: TSC gene-associated lesions of the lung. https://t.co/8Nin5hxAgx #pathology #PathTwitter #PathX #pulmpath

[Amer Swid @AmerSwid]

Reactive mesothelium vs malignancy.....subtle differences, BUT major consequences!!!

[Dr Rishabh Jain @DrRishabhOnco]

🩺 THE 10 MOST IMPORTANT GI CANCER TRIALS OF #ASCO26

🌟 PLENARY & PRACTICE-CHANGERS

1️⃣ RASolute 302 (LBA5)
Daraxonrasib (RMC-6236) vs chemotherapy in metastatic pancreatic cancer
Can RAS finally become druggable in pancreatic cancer?

2️⃣ CIRCULATE (LBA3500)
ctDNA-guided adjuvant therapy in stage II colon cancer
Potentially the defining trial for escalation and de-escalation strategies.

3️⃣ EMERALD-3
Durvalumab + tremelimumab + lenvatinib + TACE in unresectable HCC
How aggressive should frontline liver cancer therapy become?

🧬 COLORECTAL CANCER PRECISION ERA

4️⃣ BREAKWATER Cohort 3 (LBA3503)
Encorafenib + cetuximab + FOLFIRI in BRAF V600E mCRC
Important real-world sequencing data beyond oxaliplatin-based therapy.

5️⃣ SWOG S2107
Sequencing optimization in BRAF V600E metastatic CRC
A major unmet-need clinical question.

6️⃣ STELLAR Update
Long-term survival update for TNT in rectal cancer
Do pCR gains translate into durable survival benefit?

🎯 GASTRIC, GEJ & RARE GI SUBTYPES

7️⃣ HERIZON-GEA-01 (4010)
Zanidatamab-based frontline therapy in HER2+ gastric/GEJ cancer
Could bispecific HER2 targeting redefine frontline care?

8️⃣ KEYNOTE-811 Mature OS
Final long-term OS update for pembrolizumab + trastuzumab + chemotherapy
Clinicians have been waiting for these mature survival curves.

9️⃣ ATTRACTION-6 Update
Checkpoint inhibitor strategies in advanced gastroesophageal cancers
The IO sequencing debate continues.

🔟 Bezuclastinib + Sunitinib (11500)
Phase III data in advanced GIST
A key resistance-targeting strategy in rare GI oncology.

Which GI abstract will change your clinic most?

#GIOnc #OncTwitter #ASCO26 #PanCan #ColorectalCancer #MedTwitter @ASCO @myesmo @esmo_open @OncoAlert

[Diego A. Díaz-García @diegoadiazg]

🎯 Antibody-Drug Conjugates: Expanding Clinical Impact.

ADCs are rapidly reshaping oncology across hematologic and solid tumors, combining targeted delivery with highly potent payloads.

As these agents move into earlier-stage disease and combination strategies, key challenges emerge: biomarker selection, resistance mechanisms, toxicity management, and optimal sequencing.

Next-generation ADC design may further expand efficacy, but careful patient selection will remain essential.

📖 Cell
DOI 👉🏻 https://t.co/3R5JSliiuL

#CánCare #oncology #ADC #precisiononcology #immunotherapy

[Dr. Arkadip MD @pathognosis22]

#Grossing essentials! Organ normal dimensions and weights #pathresident #pathology #grays #anatomy

[Dr. Arkadip MD @pathognosis22]

Hey! A short illustration on the approach of #lymphoma! Hope it may help! #pathology #pathresident #pathognosis

[Dr. Arkadip MD @pathognosis22]

Daily #breast #pathology reporting companion for #beginners #pathognosis

[Dr. Arkadip MD @pathognosis22]

General brief overview of some well-known #tumor #markers #pathology #serology #immunology #CA125 #CEA #beta_hCG #AFP #PSA #clinics #lab #lab_report #report #pathognosis

[Dr. Arkadip MD @pathognosis22]

The #Milan System - Salivary gland #milan #salivary #ACC #AdCC #PA #warthin #MEC #EMC #SDC #SCC #pathology #pathognosis #cytology

[Dr. Arkadip MD @pathognosis22]

The #Bethesda System - cervix - squamous cell #TBS #cervix #LSIL #HSIL #SCC #pathology #pathognosis #cytology

[Dr. Arkadip MD @pathognosis22]

The #Bethesda System - thyroid #TBS #thyroid #AUS #FLUS #FN #FTC #PTC #MTC #ATC #PDTC #WHO #pathology #pathognosis #cytology

[Dr Rishabh Jain @DrRishabhOnco]

🚨 THE 15 MOST IMPORTANT TRIALS OF #ASCO26

May 29 - June 2 | Chicago
Which trial are you watching most closely?

🌟 PLENARY GAME-CHANGERS

1️⃣ PROTEUS
Perioperative apalutamide + ADT in high-risk localized prostate cancer

2️⃣ LIBRETTO-432
Adjuvant selpercatinib in RET+ NSCLC

3️⃣ HARMONi-6
Ivonescimab + chemo vs tislelizumab + chemo in squamous NSCLC

4️⃣ RASolute 302
Daraxonrasib (RMC-6236) in metastatic pancreatic cancer

5️⃣ SARC041
Abemaciclib in dedifferentiated liposarcoma

⚡ FRONTLINE & PERIOPERATIVE SHIFTS

6️⃣ KEYNOTE-B15 / EV-304
EV + pembrolizumab vs chemo in MIBC

7️⃣ LITESPARK-022
Pembrolizumab + belzutifan in adjuvant ccRCC

8️⃣ AMBITION
Paclitaxel/bevacizumab ± atezolizumab in HR+ breast cancer

9️⃣ NeoADAURA
Neoadjuvant osimertinib in EGFR+ NSCLC

🔟 A-DREAM
ADT interruption strategies in mCSPC

🧬 PRECISION, ADCs & NEXT-GEN IMMUNOLOGY

1️⃣1️⃣ DESTINY-Breast06
T-DXd expands into HER2-ultralow disease

1️⃣2️⃣ CROWN (7-year update)
Lorlatinib durability in ALK+ NSCLC

1️⃣3️⃣ DeLLphi-312
Tarlatamab in frontline SCLC

1️⃣4️⃣ COMMIT
Atezolizumab + FOLFOX/Bev in MSI-H mCRC

1️⃣5️⃣ IMvigor011
ctDNA-guided adjuvant atezolizumab in bladder cancer

#OncoTwitter #MedTwitter #ASCO26 #CancerResearch @OncoAlert @ASCO @JCOPO_ASCO @OncBrothers

[Elliot K Fishman / CTisus.com @ctisus]

NEW! 3 new Chest CT Quick Guides

- Invasive Aspergillosis
- Pulmonary Edema
- Pulmonary Fibrosis

https://t.co/vf63ekdrsT

[Uğur Özkerim @UOzkerim]

The evolution of resectable NSCLC in one figure. 🫁

From postoperative immunotherapy…
to perioperative strategies with consistently stronger efficacy signals across phase 3 trials.

The field is rapidly redefining the standard of care
@t_mitsudomi 👏👏

@OncoAlert @OncoReporte @MedwatchKate @StephenVLiu @GlopesMd @MedicalwatchHQ